Beyond cardiovascular risk: The impact of obesity on cancer death

Cleveland Clinic Journal of Medicine

Volumn 73, Issue 10, 2006, Pages 945-950

  Bordeaux, Bryan C ^a,b   Bolen, Shari ^a   Brotman, Daniel J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INSULIN; SEX HORMONE; SOMATOMEDIN C;

BODY MASS; CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER THERAPY; CARCINOGENESIS; CARDIOVASCULAR RISK; COMORBIDITY; DEATH; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; OBESITY; PATIENT CARE; RADIATION DOSE; REVIEW; SCREENING TEST; SOCIAL STATUS;

EID: 33750071396     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.10.945     Document Type: Review

References (47)

1. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004, 291:2847-2850.
2. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004; 89:2522-2525.
3. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005; 293:1861-1867.
4. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Correction: actual causes of death in the United States, 2000. JAMA 2005; 293:293-294.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
6. Whitlock G, Lewington S, Mhurchu CN. Coronary heart disease and body mass index: a systematic review of the evidence from larger prospective cohort studies. Semin Vasc Med 2002; 2:369-381.
7. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292:2471-2477.
8. Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health 2001; 22:355-375.
9. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282:1523-1529.
10. Lee ES, Kim YH, Beck S, Lee S, Oh SW. Depressive mood and abdominal fat distribution in overweight premenopausal women. Obes Res 2005; 13:320-325.
11. Osler M. Obesity and cancer. A review of epidemiological studies on the relationship of obesity to cancer of the colon, rectum, prostate, breast, ovaries, and endometrium. Dan Med Bull 1987; 34:267-274.
12. Calle EE, Rodriguez C, Walker-Thummond K, Thun MJ. Overweight obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625-1638.
13. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4:579-591.
14. World Health Organization. IARC/WHO handbook of cancer prevention. 1st ed. Lyon: IARC Press; 2002. Weight control and physical activity, vol 6.
15. Jee SH, Kim HJ, Lee J. Obesity, insulin resistance and cancer risk. Yonsei Med J 2005; 46:449-455.
16. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293:194-202.
17. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21:215-244.
18. Frystyk J. Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factors in human obesity. Metabolism 1995; 44(suppl 4):37-44.
19. Nam SY, Lee EJ, Kim KR, et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 1997, 21:355-359.
20. Jenkins PJ. Acromegaly and cancer. Horm Res 2004, 62(suppl 1):108-115.
21. Dandona P Aljada A. Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111:1448-1454.
22. Key TJ, Appleby PN, Reeves GK, et al; Endogenous Hormones Breast Cancer Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95:1218-1226.
23. Antunes CM, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 1979; 300:9-13.
24. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
25. Rosen AB, Schneider EC. Colorectal cancer screening disparities related to obesity and gender. J Gen Intern Med 2004; 19:332-338.
26. Wee CC, McCarthy EP, Davis RB, Phillips RS. Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med 2000; 132:697-704.
27. Wee CC, Phillips RS, McCarthy EP. BMI and cervical cancer screening among white, African-American, and Hispanic women in the United States. Obes Res 2005; 13:1275-1280.
28. Lipscombe LL, Hux JE, Booth GL Reduced screening mammography among women with diabetes. Arch Intern Med 2005; 165:2090-2095.
29. Lubitz RM, Litzelman DK, Ditus RS, Tierney WM. Is obesity a barrier to physician screening for cervical cancer? Am J Med 1995; 98:491-496.
30. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004, 13:47-55.
31. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103:1092-1095.
32. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res 2003; 11:1223-1231.
33. Drewnowski A, Specter SE. Poverty and obesity: the role of energy density and energy costs. Am J Clin Nutr 2004; 79:6-16.
34. Woolhandler S, Himmelstein DU. Reverse targeting of preventive care due to lack of health insurance. JAMA 1988, 259:2872-2874.
35. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol 2005; 174:1798-1801.
36. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004; 22:446-453.
37. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 20134, 22:648-657.
38. Modesitt SC, van Nagell JR Jr. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv 2005; 60:683-692.
39. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development treatment and outcomes of cancer. Nat Clin Pract Oncol 2005, 2:48-53.
40. Grigg A. Harun MH, Szer J. Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey. Leuk Lymphoma 1997; 25:487-491.
41. Colleoni M, Li S, Gelber RD, et al; International Breast Cancer Study Group. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 2005; 366:1108-1110.
42. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165:1267-1273.
43. Berclaz G, Li S, Price KN, et al; International Breast Cancer Study Group. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004; 15:875-884.
44. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 1994; 120:18-25.
45. Luchka K, Shalev S. Pelvic irradiation of the obese patient: a treatment strategy involving megavoltage simulation and intratreatment setup corrections. Med Phys 1996; 23:1897-1902.
46. Kupets R, Covens A. Strategies for the implementation of cervical and breast cancer screening of women by primary care physicians. Gynecol Oncol 2001; 83:186-197.
47. Rosenthal MB, Frank RG, Li Z, Epstein AM. Early experience with pay-for-performance: from concept to practice. JAMA 2005; 294:1788-1793.